161 related articles for article (PubMed ID: 21934576)
1. Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposure.
Coseo SE; Porras C; Dodd LE; Hildesheim A; Rodriguez AC; Schiffman M; Herrero R; Wacholder S; Gonzalez P; Sherman ME; Jimenez S; Solomon D; Bougelet C; van Doorn LJ; Quint W; Safaeian M;
Sex Transm Dis; 2011 Oct; 38(10):976-82. PubMed ID: 21934576
[TBL] [Abstract][Full Text] [Related]
2. Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica.
Coseo S; Porras C; Hildesheim A; Rodriguez AC; Schiffman M; Herrero R; Wacholder S; Gonzalez P; Wang SS; Sherman ME; Jimenez S; Solomon D; Bougelet C; van Doorn LJ; Quint W; Safaeian M;
Sex Transm Dis; 2010 Nov; 37(11):706-14. PubMed ID: 20661178
[TBL] [Abstract][Full Text] [Related]
3. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections.
Safaeian M; Porras C; Schiffman M; Rodriguez AC; Wacholder S; Gonzalez P; Quint W; van Doorn LJ; Sherman ME; Xhenseval V; Herrero R; Hildesheim A;
J Natl Cancer Inst; 2010 Nov; 102(21):1653-62. PubMed ID: 20944077
[TBL] [Abstract][Full Text] [Related]
4. Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus.
Robbins HA; Li Y; Porras C; Pawlita M; Ghosh A; Rodriguez AC; Schiffman M; Wacholder S; Kemp TJ; Gonzalez P; Schiller J; Lowy D; Esser M; Matys K; Quint W; van Doorn LJ; Herrero R; Pinto LA; Hildesheim A; Waterboer T; Safaeian M
BMC Infect Dis; 2014 Mar; 14():120. PubMed ID: 24588945
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.
Robbins HA; Waterboer T; Porras C; Kemp TJ; Pawlita M; Rodriguez AC; Wacholder S; Gonzalez P; Schiller JT; Lowy DR; Esser M; Matys K; Poncelet S; Herrero R; Hildesheim A; Pinto LA; Safaeian M
Hum Vaccin Immunother; 2014; 10(10):2965-74. PubMed ID: 25483632
[TBL] [Abstract][Full Text] [Related]
6. Determinants of seropositivity among HPV-16/18 DNA positive young women.
Porras C; Bennett C; Safaeian M; Coseo S; Rodríguez AC; González P; Hutchinson M; Jiménez S; Sherman ME; Wacholder S; Solomon D; van Doorn LJ; Bougelet C; Quint W; Schiffman M; Herrero R; Hildesheim A;
BMC Infect Dis; 2010 Aug; 10():238. PubMed ID: 20698998
[TBL] [Abstract][Full Text] [Related]
7. Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates.
Lang Kuhs KA; Porras C; Schiller JT; Rodriguez AC; Schiffman M; Gonzalez P; Wacholder S; Ghosh A; Li Y; Lowy DR; Kreimer AR; Poncelet S; Schussler J; Quint W; van Doorn LJ; Sherman ME; Sidawy M; Herrero R; Hildesheim A; Safaeian M;
Am J Epidemiol; 2014 Sep; 180(6):599-607. PubMed ID: 25139208
[TBL] [Abstract][Full Text] [Related]
8. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16.
Kirnbauer R; Hubbert NL; Wheeler CM; Becker TM; Lowy DR; Schiller JT
J Natl Cancer Inst; 1994 Apr; 86(7):494-9. PubMed ID: 8133532
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a prototype real-time PCR assay for carcinogenic human papillomavirus (HPV) detection and simultaneous HPV genotype 16 (HPV16) and HPV18 genotyping.
Castle PE; Sadorra M; Lau T; Aldrich C; Garcia FA; Kornegay J
J Clin Microbiol; 2009 Oct; 47(10):3344-7. PubMed ID: 19675214
[TBL] [Abstract][Full Text] [Related]
10. Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial.
Safaeian M; Sampson JN; Pan Y; Porras C; Kemp TJ; Herrero R; Quint W; van Doorn LJ; Schussler J; Lowy DR; Schiller J; Schiffman MT; Rodriguez AC; Gail MH; Hildesheim A; Gonzalez P; Pinto LA; Kreimer AR;
J Natl Cancer Inst; 2018 Feb; 110(2):205-12. PubMed ID: 28954299
[TBL] [Abstract][Full Text] [Related]
11. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial.
Safaeian M; Porras C; Pan Y; Kreimer A; Schiller JT; Gonzalez P; Lowy DR; Wacholder S; Schiffman M; Rodriguez AC; Herrero R; Kemp T; Shelton G; Quint W; van Doorn LJ; Hildesheim A; Pinto LA;
Cancer Prev Res (Phila); 2013 Nov; 6(11):1242-50. PubMed ID: 24189371
[TBL] [Abstract][Full Text] [Related]
12. A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study.
Wentzensen N; Rodriguez AC; Viscidi R; Herrero R; Hildesheim A; Ghosh A; Morales J; Wacholder S; Guillen D; Alfaro M; Safaeian M; Burk RD; Schiffman M
J Infect Dis; 2011 Jul; 204(1):94-102. PubMed ID: 21628663
[TBL] [Abstract][Full Text] [Related]
13. Comparison of two PCR-based human papillomavirus genotyping methods.
Castle PE; Porras C; Quint WG; Rodriguez AC; Schiffman M; Gravitt PE; González P; Katki HA; Silva S; Freer E; Van Doorn LJ; Jiménez S; Herrero R; Hildesheim A;
J Clin Microbiol; 2008 Oct; 46(10):3437-45. PubMed ID: 18716224
[TBL] [Abstract][Full Text] [Related]
14. Polymer-based enzyme-linked immunosorbent assay using human papillomavirus type 16 (HPV16) virus-like particles detects HPV16 clade-specific serologic responses.
Studentsov YY; Ho GY; Marks MA; Bierman R; Burk RD
J Clin Microbiol; 2003 Jul; 41(7):2827-34. PubMed ID: 12843008
[TBL] [Abstract][Full Text] [Related]
15. Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial.
Lang Kuhs KA; Gonzalez P; Rodriguez AC; van Doorn LJ; Schiffman M; Struijk L; Chen S; Quint W; Lowy DR; Porras C; DelVecchio C; Jimenez S; Safaeian M; Schiller JT; Wacholder S; Herrero R; Hildesheim A; Kreimer AR;
J Infect Dis; 2014 Dec; 210(12):1890-9. PubMed ID: 24958910
[TBL] [Abstract][Full Text] [Related]
16. Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial.
Safaeian M; Kemp TJ; Pan DY; Porras C; Rodriguez AC; Schiffman M; Cortes B; Katki H; Wacholder S; Schiller JT; Gonzalez P; Penrose K; Lowy DR; Quint W; van Doorn LJ; Herrero R; Hildesheim A; Pinto LA
Hum Vaccin Immunother; 2013 Jul; 9(7):1399-406. PubMed ID: 23571174
[TBL] [Abstract][Full Text] [Related]
17. Correlation between cervical HPV DNA detection and HPV16 seroreactivity measured with L1-only and L1+L2 viral capsid antigens.
Trevisan A; Candeias JMG; Thomann P; Villa LL; Franco EL; Trottier H; The Ludwig-McGill Study Group
J Med Microbiol; 2020 Jul; 69(7):960-970. PubMed ID: 32510304
[No Abstract] [Full Text] [Related]
18. Prevalence of and risk factors for oral human papillomavirus among young women in Costa Rica.
Lang Kuhs KA; Gonzalez P; Struijk L; Castro F; Hildesheim A; van Doorn LJ; Rodriguez AC; Schiffman M; Quint W; Lowy DR; Porras C; Delvecchio C; Katki HA; Jimenez S; Safaeian M; Schiller J; Solomon D; Wacholder S; Herrero R; Kreimer AR;
J Infect Dis; 2013 Nov; 208(10):1643-52. PubMed ID: 24014882
[TBL] [Abstract][Full Text] [Related]
19. Empirical sample-specific approaches to define HPV16 and HPV18 seropositivity in unvaccinated, young, sexually active women.
Ng K; Morais S; Wissing MD; Burchell AN; Tellier P-P; Coutlée F; Waterboer T; El-Zein M; Franco EL
Microbiol Spectr; 2024 Jun; 12(6):e0022924. PubMed ID: 38687066
[TBL] [Abstract][Full Text] [Related]
20. Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection.
Beachler DC; Kreimer AR; Schiffman M; Herrero R; Wacholder S; Rodriguez AC; Lowy DR; Porras C; Schiller JT; Quint W; Jimenez S; Safaeian M; Struijk L; Schussler J; Hildesheim A; Gonzalez P;
J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26467666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
